SpringWorks' non-cancerous tumor drug to be priced at $29K per month in U.S.

By Reuters
| November 29, 2023

The monotherapy nirogacestat, branded as Ogsiveo, became the first approved treatment for desmoid tumors.

Full story

#1

Recent research on Paxlovid shows there is "solid data on its effectiveness," a co-author of the study told HealthLeaders. ...

A new personal protective equipment manufacturing company is set to open in Cincinnati next year. ...